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PPeripheral Vascular Disease
A High Ankle-Brachial Index Is
Associated With Increased Cardiovascular
Disease Morbidity and Lower Quality of Life
Matthew A. Allison, MD, MPH,* William R. Hiatt, MD,‡ Alan T. Hirsch, MD,¶
Joseph R. Coll, PHD,§ Michael H. Criqui, MD, MPH*†
San Diego, California; Denver, Colorado; Minneapolis, Minnesota
Objectives The purpose of this study is to determine if an ankle-brachial index (ABI) 1.40 is associated with reduced qual-
ity of life (QoL).
Background Ankle-brachial index values 1.40 have been associated with some cardiovascular disease (CVD) risk factors
and increased mortality, but the relationship to other disease morbidity such as reduced QoL has not been previ-
ously evaluated.
Methods The PARTNERS (PAD Awareness, Risk and Treatment: New Resources for Survival) program was a national
cross-sectional study of 7,155 patients age 50 years recruited from 350 primary care sites. All sites performed
the ABI using a Doppler device and a standardized technique.
Results A total of 296 subjects had an ABI 1.40 in at least 1 leg, and 4,420 had an ABI between 0.90 and 1.40. Dia-
betes, male gender, and waist circumference were positively associated with a high ABI, and smoking and dys-
lipidemia were inversely associated with a high ABI. After adjustment for age, gender, and the traditional CVD
risk factors, and accounting for multiple comparisons, the high ABI group had significantly higher odds for foot
ulcers (p  0.005) and borderline associations with heart failure, stroke, and neuropathy. After the same adjust-
ments and adjusting for patients with other CVD, the high ABI group scored 2.0 points lower on the physical
component scale on the Medical Outcomes Study Standard Form–36 and 5.5 points lower on the Walking Im-
pairment Questionnaire walking distance domain (p  0.05 for both).
Conclusion Individuals with a high ABI have higher odds for foot ulcers and neuropathy, as well as lower scores on some
physical functioning QoL domains. (J Am Coll Cardiol 2008;51:1292–8) © 2008 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.064c
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Phe ankle-brachial index (ABI) provides information on the
resence of systemic atherosclerosis and associated cardio-
ascular risk. For example, individuals with an ABI 0.90
ave an elevated risk for incident cardiovascular disease
CVD) morbidity (1,2) and mortality events (3–5). Recent
tudies indicate, however, that dichotomizing the ABI using
he 0.90 cut point may lead to underdiagnosis, because
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Manuscript received May 21, 2007; revised manuscript received November 19,
007, accepted November 27, 2007.ohorts with an ABI 1.30 have been associated with
igher levels of many CVD risk factors (6) as well as
oronary artery calcium (7). This suggests that this upper
ut point may also be associated with higher CVD morbid-
ty. Recent studies have also documented more leg pain (8)
nd higher levels of CVD morbidity and mortality among
hose with an ABI above 1.40 (9,10). Accordingly, using
ata collected from a community-based clinic population
n the PARTNERS (PAD Awareness, Risk and Treat-
ent: New Resources for Survival) program, the aim of
his study was to determine the risk factors, comorbid
VD conditions, and quality of life (QoL) associated
ith an ABI 1.40.
ethods
detailed description of the methods used in the
ARTNERS program has been published previously (11).
n brief, PARTNERS was a cross-sectional survey of
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April 1, 2008:1292–8 High Ankle-Brachial Index in the PARTNERS Programeripheral arterial disease (PAD) and other CVD prevalence
nd treatment that was performed at 27 regional coordinat-
ng centers selected for their expertise in PAD care. These
egional centers identified 350 local primary care sites for
atient evaluation. The local study physician and coordina-
or identified patients who met the eligibility criteria for the
tudy. Sequential patients seen in these primary care prac-
ices underwent administration of standardized question-
aires, a review of their medical history, height, weight,
lood pressure, and waist circumference, and each subject
nderwent an ABI measurement. The protocol was re-
iewed and approved by the institutional review boards at all
tudy sites, and all patients provided written informed
onsent prior to participation.
tudy population. Enrollment was based on predefined
riteria based on the known epidemiology of PAD (12–17).
pecifically, patients were enrolled if they were 70 years or
lder or if they were age 50 to 69 years and had a history of
t least 10 pack-years of cigarette smoking or diabetes or
oth. Data were collected between June and October 1999.
At the study visit, subjects were classified for the presence
f existing CVD or PAD, as well as new versus prior PAD
ased on the results of their ABI and medical history.
ubjects were considered to have prior PAD if they had
ndergone prior lower extremity arterial revascularization
egardless of their ABI value at the evaluation office visit, if
he chart review revealed earlier abnormal vascular labora-
ory studies, or if their ABI was 1.00 at the evaluation
isit. Patients with no previous history of PAD were con-
idered to have new PAD if their ABI was0.90 during the
tudy office visit. A diagnosis of existing CVD required a
ocumented history of coronary artery disease, cerebrovas-
ular disease, or abdominal aortic aneurysm repair. A
iagnosis of coronary artery disease was based on a history of
ngina (stable or unstable), myocardial infarction, percu-
aneous transluminal coronary angioplasty, or coronary ar-
ery bypass graft surgery. Patients were considered to have
erebrovascular disease if they had a history of transient
schemic attack, stroke (ischemic or hemorrhagic), or ca-
otid endarterectomy.
BI technique. Prior to study initiation, all local sites
eceived instruction and training on the accurate use of the
oppler technique and calculation of the ABI. A 5-mHz
oppler device (Elite-100R, Nicolet Vascular Inc., Golden,
olorado) was used at each site to measure the ABI. With
he subject in the supine position, systolic blood pressures
ere measured in the brachial arteries and in both the
orsalis pedis and posterior tibial arteries of the lower
xtremities. The ABI was calculated separately for each leg
y dividing the higher of the 2 ankle systolic pressures by the
igher of the 2 brachial systolic pressures. The sensitivity
nd specificity of an ABI 0.90 are both 90% for an
ngiographically defined stenosis of 50% or more in a
ajor leg artery (18). The reproducibility of the ABI isood (19,20). dlinical subgroups. The nor-
al ABI group was defined as
atients having an ABI 0.90
nd ABI1.40 in both legs. The
efinition of the high ABI group
equired that patients have an
BI 1.40 in both legs or an
BI1.40 in 1 leg and a normal
BI in the contralateral leg. In-
ividuals with an ABI 0.90 in
ither leg or a history of lower
xtremity revascularization were
lassified as having PAD and
ere excluded from this analysis.
therosclerosis risk factors.
moking was defined as 1 pack-
ear or more of tobacco use based
n patient interview or chart re-
iew. Diabetes was determined
rom the medical record, regard-
ess of whether it was type 1 or type 2. The diagnosis of
iabetes included treatment for this condition defined as
urrent use of dietary interventions or use of diabetes
edications. Laboratory screening for prevalent diabetes
as not performed. Dyslipidemia was defined from the
edical record as past or present use of lipid-lowering
gents or: 1) a total cholesterol concentration 240 mg/dl;
) low-density lipoprotein cholesterol concentration 160
g/dl; 3) high-density lipoprotein (HDL) cholesterol con-
entration of 35 mg/dl; 4) triglyceride concentration
200 mg/dl; or 5) a total cholesterol/HDL ratio of 5.0
21). Lipid-lowering therapy was defined as the prescription
f agents used to treat lipid abnormalities (e.g., statins,
iacin, fibrates, and bile acid binding resin agents). A fasting
ipid profile was not obtained as part of this program.
ypertension was defined as the self-reported use of calcium
hannel blockers, angiotensin-converting enzyme inhibi-
ors, beta-blockers, or diuretics for the indication of treat-
ent of hypertension as well as either a systolic blood
ressure 140 mm Hg or a diastolic blood pressure 90
m Hg.
uestionnaire data. Subjects were surveyed on their QoL
y completing the Medical Outcomes Study Standard
orm-36 (SF-36) and the Walking Impairment Question-
aire (WIQ). The SF-36 is composed of 2 summary measures
physical health and mental health) (22–24). Each of these
s composed of 5 scales that attempt to capture relevant
oL information by asking questions from 1 of 36 different
tems. For instance, the role physical scale consists of 4
tems that obtain information on problems with work as a
esult of physical health. The individual SF-36 scales have
een shown to have good validity among patients with
ntermittent claudication (25). The WIQ is a valid measure
f community walking ability in patients with and without
AD (26). The WIQ yields 3 summary scores: walking
Abbreviations
and Acronyms
ABI  ankle-brachial index
BMI  body mass index
CHF  congestive heart
failure
CVD  cardiovascular
disease
HDL  high-density
lipoprotein
OR  odds ratio
PAD  peripheral arterial
disease
QoL  quality of life
SF-36  Medical Outcomes
Study Standard Form-36
WIQ  Walking Impairment
Questionnaireistance, walking speed, and stair climb.
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High Ankle-Brachial Index in the PARTNERS Program April 1, 2008:1292–8tatistical analyses. Demographic characteristics and risk
actors were summarized as means and standard deviations
or continuous variables and as frequencies and percentages
or categorical variables. Differences in demographics and
isk factors between the normal and high ABI groups were
ested with a 2-sided 2-sample t test for continuous vari-
bles and with a chi-square test (or Fisher exact test) for
ategorical outcomes (Table 1). A multiple logistic regres-
ion with stepwise selection was used to determine the set of
emographic and risk factors that are independently asso-
iated with a high ABI. The prevalence of comorbid
onditions was compared between the normal and high ABI
roups using a chi-square (or Fisher exact test) and are
eported in Table 2. Logistic regression was employed to
djust the prevalence of comorbid conditions for age,
ender, race, diabetes, smoking (current, former, never),
ypertension, dyslipidemia, and body mass index (BMI).
ultiple linear regression models were used to compare the
emographic and risk-adjusted means of the SF-36 and
IQ outcomes between the normal and high ABI groups.
djustments were made for age, gender, race, diabetes,
moking (current, former, never), hypertension, dyslipide-
ia, BMI, and history of other CVD. Least-squares means
y ABI group are reported in Table 3.
Because the inclusion criteria were different based on age
t enrollment (i.e., 50 to 69 years vs. 70 years), we
Demographic and Risk Factors by ABI Group
Table 1 Demographic and Risk Factors by A
Risk Factor
Age, yrs (mean, SD)
Male, n (%)
Race/ethnicity, n (%)
Non-Hispanic white
Black
Hispanic
Native American
Asian/Pacific Islander
Other
Smoking status, n (%)
Current
Former
Never
Diabetes mellitus, n (%)
Dyslipidemia, n (%)
Hypertension, n (%)
Other CVD, n (%)
BMI (kg/mm2), mean (SD)
Waist circumference, mean (SD)
SBP (mm Hg), mean (SD)
DBP (mm Hg), mean (SD)
Left dorsalis pedis blood SBP (mm Hg), mean (SD)
Right dorsalis pedis blood SBP (mm Hg), mean (SD)
Left posterior tibial blood SBP (mm Hg), mean (SD)
Right posterior tibial SBP (mm Hg), mean (SD)*The p values are biased as these measures are used in the ABI group defin
ABI ankle brachial index; BMI bodymass index; CVD cardiovascular dncluded interactions between age and both smoking and
iabetes in the multivariable models. Inclusion of these
nteraction terms (i.e., smoking  age and diabetes  age)
id not change the magnitude or significance of the asso-
iations between the high ABI and the outcomes for this
tudy. Statistical analyses were performed using SAS version
.1 (SAS Institute Inc., Cary, North Carolina). A Bonfer-
oni correction was used to adjust the critical region for
tatistical significance due to the number of statistical tests
erformed. Ten SF-36 items, 10 WIQ items, and 13
omorbidities were tested. Statistical significance is defined
s p  0.005 (5% type I error rate divided by 10 compari-
ons per QoL instrument).
esults
ubjects. Figure 1 shows a diagram of the number of
ubjects available for analysis after the following exclusions:
) those with PAD defined as an ABI 0.90; 2) those with
issing ABIs; and 3) those with missing demographic or
isk factor covariates. There were 4,716 subjects in the
nalysis population. Also, not all subjects completed the
oL questionnaires. Therefore, only 3,215 subjects were
ncluded in the SF-36 analyses and 3,114 in the WIQ
nalyses.
roup
ABI Group
p Valueal (n  4,420) High (n  296)
70.1 (9.7) 71.1 (9.9) 0.09
,024 (45.8) 200 (67.6) 0.001
0.24
,672 (83.1) 251 (84.8)
403 (9.1) 16 (5.4)
184 (4.2) 15 (5.1)
33 (0.7) 4 (1.3)
80 (1.8) 7 (2.4)
48 (1.1) 3 (1.0)
0.001
658 (14.9) 19 (6.4)
,831 (41.4) 127 (42.9)
,931 (43.7) 150 (50.7)
,538 (34.8) 131 (44.3) 0.001
,842 (64.3) 172 (58.1) 0.03
,562 (80.6) 241 (81.4) 0.73
,544 (34.9) 124 (41.9) 0.02
28.9 (6.2) 29.6 (7.0) 0.08
38.1 (6.0) 39.6 (5.9) 0.001
37.7 (19.5) 133.5 (18.3) 0.001*
77.8 (10.4) 76.0 (10.5) 0.001
50.0 (28.9) 173.8 (46.7) 0.001*
50.4 (29.2) 175.9 (45.6) 0.001*
55.6 (27.3) 185.2 (41.2) 0.001*
56.3 (27.5) 191.8 (43.1) 0.001*BI G
Norm
2
3
1
1
1
2
3
1
1
1
1
1
1ition.
isease; DBP diastolic blood pressure; SBP systolic blood pressure.
A

a
w
r
A
8
e
d
R
d
p
A
o
l
v
HD
M
h
W
1295JACC Vol. 51, No. 13, 2008 Allison et al.
April 1, 2008:1292–8 High Ankle-Brachial Index in the PARTNERS ProgramAmong the 4,716 subjects with an ABI 0.90, the mean
BI was 1.09  0.13. Of these subjects, 296 had an ABI
1.40 in either leg, and 4,420 had an ABI between 0.90
nd 1.40. The mean (SD) age was 70.2 (9.7) and 52.8%
ere female. The majority were non-Hispanic white; of the
est, 8.9% were African American, 4.2% Hispanic, 1.8%
sian or Pacific Islander, and 0.8% Native American. Over
Comorbidities by ABI Group
Table 2 Comorbidities by ABI Group
Characteristic Comorbidities Normal (n
Angina 760
Myocardial infarction 596
CHF 344
Angioplasty 363
Coronary artery bypass 449
Transient ischemic attack 221
Stroke 236
Carotid endarterectomy 84
Aneurysm 39
Foot ulcer 64
Neuropathy 565
Venous thrombosis 177
Joint disease/rheumatoid arthritis 1,671
Values are expressed as n (%).
CHF  congestive heart failure; other abbreviations as in Table 1.
RQoL Adjusted forem graphic and Risk Factors by ABI Group
Table 3 HRQoL Adjusted forDemographic and Risk Factors by ABI Group
Characteristic
ABI Group
p Value
Normal
(n  4,420)
High
(n  296)
SF-36 scores
Body pain 60.0 58.5 0.42
General health 59.1 56.0 0.04
Mental health 71.8 70.8 0.40
Physical functioning 59.0 55.4 0.05
Role, emotional 65.4 63.9 0.59
Role, physical 52.5 45.3 0.01
Social functioning 75.7 74.4 0.44
Vitality 54.1 51.4 0.08
Mental composite score 49.9 49.9 0.99
Physical composite score 39.9 37.8 0.01
WIQ scores
Calf pain 68.2 66.9 0.55
Chest pain 85.7 87.9 0.15
Dyspnea 74.0 76.0 0.32
Heart palpitations 84.2 85.7 0.36
Joint pain 59.6 57.1 0.27
Other problems 81.3 78.6 0.19
Stair climbing 58.2 55.4 0.19
Walking distance 65.6 60.1 0.04
Walking speed 52.6 48.3 0.03
Weakness 68.3 65.5 0.20
eans are adjusted for age, gender, race, smoking, diabetes, hypertension, dyslipidemia, BMI, and
istory of other CVD.
HRQoL  health-related quality of life; SF-36  Medical Outcomes Study Standard Form–36;
IQ  Walking Impairment Questionnaire; other abbreviations as in Table 1.0% were hypertensive, 64% had high cholesterol, 56% were
ither current or former cigarette smokers, and 35% were
iagnosed with diabetes mellitus.
isk factors for an ABI >1.40. A comparison of the
emographic and CVD risk factors by ABI group is
rovided in Table 1. Compared with those with a normal
BI, subjects with a high ABI had significantly lower levels
f brachial artery systolic and diastolic blood pressure, a
ower prevalence of dyslipidemia, and smoked less. Con-
ersely, the high ABI group had significantly higher mea-
ABI Group
p Value20) High (n  296)
58 (20.0) 0.28
45 (15.5) 0.40
38 (13.1) 0.002
34 (11.7) 0.05
43 (14.7) 0.02
21 (7.2) 0.11
26 (8.9) 0.01
6 (2.1) 0.86
2 (0.7) 0.99
13 (4.5) 0.001
58 (20.2) 0.001
17 (5.9) 0.14
92 (32.1) 0.03
Figure 1 Flow Diagram of Subjects Available for Analysis
ABI  ankle-brachial index; PAD  peripheral arterial disease. 4,4
(17.5)
(13.7)
(7.9)
(8.4)
(10.3)
(5.1)
(5.4)
(1.9)
(0.9)
(1.5)
(13.2)
(4.1)
(38.6)
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High Ankle-Brachial Index in the PARTNERS Program April 1, 2008:1292–8ured levels of each ankle systolic pressure, as well as a
igher prevalence of diabetes mellitus and other CVD. The
igh ABI group had significantly more males and a larger
aist circumference.
A multiple stepwise logistic regression model identified a
ositive association of male gender (odds ratio [OR] 2.45,
5% confidence interval [CI] 1.90 to 3.26), diabetes (OR
.30, 95% CI 1.01 to 1.68), and waist circumference (OR
.27, 95% CI 1.02 to 1.59 per 10-inch increase) with a high
BI and a negative association with dyslipidemia (OR 0.72,
5% CI 0.57 to 0.93), current smoking (OR 0.33, 95% CI
.20 to 0.55), and former smoking (OR 0.69, 95% CI 0.57
o 0.93).
ardiovascular and other comorbid diseases. Table 2
rovides the prevalences by ABI group and unadjusted
values for the CVD comorbidities. After adjustment for
ge, gender, race, smoking, diabetes, hypertension, dyslipi-
emia, and BMI, those with a high ABI had a significantly
igher prevalence of foot ulcers (OR 2.67, 95% CI 1.42 to
.02, p  0.005). The adjusted odds ratios with 95%
onfidence limits for ABI group in predicting the comor-
idity are displayed in Figure 2. As shown, marginally
ignificant associations (p  0.05) of high ABI were found
or congestive heart failure (CHF) (OR 1.58, 95% CI 1.09
o 2.30), stroke (OR 1.66, 95% CI 1.07 to 2.56), and
europathy (OR 1.51, 95% CI 1.09 to 2.08).
uality of life. Demographic and risk factor–adjusted
eans for the SF-36 and WIQ are presented in Table 3.
djustment for age, gender, race, BMI, diabetes, dyslipide-
Figure 2 Odds Ratios for CVD Comorbidities in Those With an A
Compared with those with a normal ABI, individuals with a high ABI have significantly h
Odds ratios are adjusted for age, gender, race, smoking, diabetes, hypertension, dysliia, hypertension, cigarette smoking, and history of other
VD revealed marginally significant reductions (p 
.05) in QoL in the high ABI group for the general
ealth (3.1 points), physical functioning (3.5 points), role
hysical (7.2 points), and physical component summary
cales (2.0 points). Similarly, after adjusting for demo-
raphic and risk factors, the mean score for WIQ walking
istance was marginally lower in the high ABI group by
.5 points (p  0.04) and was marginally lower for the
alking speed score by 4.3 points (p  0.03) compared
ith the normal ABI group.
iscussion
n this large national study of a primary care–derived
opulation and among those with an ABI 1.40, 6.3% had
n ABI 1.40 in at least 1 leg. Persons with a high ABI
ere more likely to be male and have diabetes and less likely
o report current or former smoking and dyslipidemia. This
s not the typical atherosclerosis risk profile as previously
escribed for patients with coronary artery disease or PAD.
pecifically, diabetes remained associated with a high ABI,
s has been previously reported, but the reduced prevalence
f smoking in this cohort has been observed in at least 1
ther large prospective study (27) and remains difficult to
xplain.
An ABI 1.40 was associated with foot ulcers, and there
ere marginal associations for CHF, stroke, and neuropa-
hy. Although these findings were adjusted for diabetes,
1.40 Compared With an ABI Between 0.90 and 1.40
odds for congestive heart failure, stroke, foot ulcers, and neuropathy.
ia, and body mass index. ABI  ankle-brachial index; CVD  cardiovascular disease.BI >
igher
pidem
s
S
b
p
a
d
m
P
t
r
W
u
i
h
m
c
i
f
t
w
a
p
t
o
r
d
(
s
h
a
p
f
s
N
t
m
s
a
s
s
d
v
i
s
p
a
r
a
(
a
S
o
t
r
1
b
w
d
i
C
b
i
d
w
A
t
t
m
s
a
i
l
w
t
o
c
T
r
t
C
T
s
e
l
n
f
s
m
i
t
p
t
t
R
3
9
R
1297JACC Vol. 51, No. 13, 2008 Allison et al.
April 1, 2008:1292–8 High Ankle-Brachial Index in the PARTNERS Programome residual confounding is a possibility. None of the
F-36 or WIQ adjusted means were statistically different
etween the normal and high ABI groups (when using a
 0.005 to account for multiple tests). However, after
ccounting for multiple comparisons, several marginal QoL
ifferences were found in measures of physical, but not
ental, health as has been previously noted in patients with
AD (28).
The physiological mechanism resulting in an ABI above
he normal range is usually assumed to be mechanical
igidity of the arteries in the lower extremities (29).
hether this is true for only modest ABI elevations is
ncertain. For example, compared with those with an ABI
n the normal range, individuals with a high ABI had much
igher levels of systolic blood pressure in the ankles and
odestly lower brachial artery systolic blood pressures
ompared with those with a normal ABI. Because the ABI
s a ratio of systolic blood pressures, a high ABI could result
rom low brachial or high ankle pressures or both. Although
he results here support the “both” hypothesis, compared
ith the normal ABI groups, the absolute differences for the
nkle pressures were much greater than for the brachial
ressures. If generalized reduced arterial compliance were
he major mechanism leading to a modest ABI elevation,
ne would anticipate higher brachial pressures and a higher
ate of hypertension in the high ABI cohort. This was not
emonstrated in our study, and results from the ARIC
Atherosclerosis Risk in Communities) study (27) cohort
howed a lower prevalence of hypertension in those with a
igh ABI. These results indicate that the factors that lead to
modestly high ABI are likely due to a complex vascular
athophysiology.
In the current study, diabetes was a significant risk factor
or a high ABI. In many studies, diabetes has also been
hown to be a risk factor for an ABI 0.90 (13,30–32).
otably, the effects of diabetes are complex, as this condi-
ion is associated with both atherosclerosis (i.e., the accu-
ulation of atherosclerotic plaques resulting in flow limiting
tenosis) (33–36) and medial calcification of the peripheral
rteries (37–39). Unfortunately, there is a paucity of re-
earch on diabetes and upper extremity atherosclerosis (i.e.,
ubclavian stenosis). In a study by Shadman et al. (40),
iabetes was associated with a 10% higher risk for subcla-
ian stenosis, but this difference was not statistically signif-
cant. It is unlikely that upper extremity subclavian athero-
clerosis contributes to the high ABI values, as both brachial
ressures were low and bilateral high-grade upper extremity
therosclerotic occlusive has not been observed in these
elatively healthy populations.
From a community-based study of non-Hispanic whites
nd African Americans, the Cardiovascular Health Study
10) has previously reported a nearly 60% higher risk for
ll-cause mortality among those with an ABI 1.40.
imilarly, the Strong Heart Study (9) reported relative risks
f 1.77 and 2.09 for all-cause and CVD mortality, respec-
ively, for those with an ABI above this same level. Thisesult has been confirmed in a recent meta-analysis (41) of
6 studies internationally, although 1 exception (27) has
een reported. Although the PARTNERS participants
ere not followed for incident CVD events, these data
emonstrate that an ABI 1.40 was associated with signif-
cantly higher odds for foot ulcers and possibly several other
VD morbidities.
There is a gap in the literature on the relationship
etween a high ABI and measures that describe the health
mpact of vascular disease beyond vital status. One such
omain is QoL. Accordingly, a primary focus of this study
as to determine the relationship of high versus normal
BI values to several QoL domains. A suggestive associa-
ion was found between an ABI 1.40 and walking dis-
ance, although this was nonsignificant after correction for
ultiple comparisons. It is well-known that there is a
ignificant (albeit weak) correlation between low ABI values
nd functional limitations associated with walking (e.g.,
ntermittent claudication) (42,43). These data provide pre-
iminary evidence that a high ABI is also associated with
alking impairment, although the mechanism underlying
his observation remains obscure. Of note, the measurement
f the ABI was conducted at 27 regional centers and 350
linical sites across the U.S. and with minimal training.
herefore, there is a possibility of misclassification and the
esults presented likely represent conservative estimates of
he associations.
onclusions
he implications of this study are 3-fold. First, clinicians
hould consider the potential clinical significance of the
ntire range of ABI values when evaluating a patient for
ower extremity arterial disease (e.g., high ABI values are
ot “normal”). Second, diabetic patients are at higher risk
or either a high or low ABI (44). Third, a high ABI is now
hown to be associated with decrements in some QoL
easures, as well as CVD morbidity. Accordingly, future
nvestigation may be warranted to evaluate the mechanism
hat underlies the derivation of the high ABI value and
erhaps the effect of aggressive risk factor management of
hese patients in an effort to improve QoL while decreasing
he risk for untoward CVD events.
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